RxDoctor Payments Data

Craig Garfield, DO

Family Medicine · Philadelphia, PANPI 1174575849

Payments from drug & device makers

$13,220in general payments, 2019–2025

Across 749 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$859
  • AbbVie$852
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$13,193100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,220 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$38,795
Medicare patients
132
Services billed
673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$79,122
XareltoRivaroxaban70$72,936
OzempicSemaglutide61$70,577
Trelegy ElliptaFluticasone/Umeclidin/Vilanter88$67,206
TrulicityDulaglutide47$66,940
JardianceEmpagliflozin44$46,017
FarxigaDapagliflozin Propanediol36$38,845
JanuviaSitagliptin Phosphate37$31,649
MounjaroTirzepatide21$27,852
EntrestoSacubitril/Valsartan20$19,447
WegovySemaglutide15$19,356
TradjentaLinagliptin16$15,394
LinzessLinaclotide19$9,669
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$9,649
Atorvastatin Calcium829$9,139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,307$94,79268 claims
Novo NordiskOzempic, Wegovy$1,496$89,93376 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,866$84,932128 claims
PfizerEliquis$693$79,12288 claims
Johnson & JohnsonXarelto$337$72,93670 claims
Boehringer IngelheimJardiance, Tradjenta$859$61,41160 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,483$51,22064 claims
MerckJanuvia$456$31,64937 claims
NovartisEntresto$187$19,44720 claims
AbbVieLinzess$852$9,66919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →